AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06426810 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrosurgical bipolar system (LigaSure)
Description: Study participants using a electrosurgical bipolar energy system will undergo sentinel lymph node biopsy using only LigaSure during the surgery.
Study NCT06045884 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sono-guided injection
Description: After general anesthesia, patients will be injected around femoral nerve using ultrasonography.
Study NCT06045884 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sono-guided injection
Description: After general anesthesia, patients will be injected around femoral nerve using ultrasonography.
Study NCT06045884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine injection
Description: After general anesthesia, patients will be injected 20ml ropivacaine around femoral nerve.
Study NCT06045884 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline injection
Description: After general anesthesia, patients will be injected 20ml 0.9% saline around femoral nerve.
Study NCT04927143 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: App-Based Contingency Management
Description: Participants will receive financial incentives for submitting randomly generated drug-negative saliva tests across the intervention period.
Study NCT04927143 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sham Control
Description: Participants get access to the DynamiCare app but will not be provided with financial incentives.
Study NCT05072769 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Date Fruit
Description: Within the first hour after birth, 100gr (5-6 pieces) dates will be eaten.
Study NCT04414787 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PCplanner
Description: PCplanner-augmented care. The PCplanner mobile app will allow patients / family members to report their needs in a platform viewable by ICU physicians. Should the needs not improve over time, the palliative care team will be activated to contribute to care.
Study NCT06430918 — intervention group
Intervention type: OTHER
Intervention: physical examination, questionnaires and inventories
Description: Questionnaires and inventories related to primary end secondary outcomes will be applied and physical examination will be performed.
Study NCT04939116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANG-3070
Description: Orally administered tyrosine kinase inhibitor capsule
Study NCT06463717 — intervention group
Intervention type: DRUG
Intervention: Transplant, Autologous
Description: High-dose melphalan followed by autologous stem cell transplantation
Study NCT06463717 — intervention group
Intervention type: DRUG
Intervention: Chemotherapy drug
Description: Regimen such as Bortezomib plus Lenalidomide plus Dexamethasone
Study NCT05899920 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Blood samples will be taken for pharmacokinetics and pharmacogenetics
Description: To assess antihypertensive drugs concentration (lisinopril, valsartan, amlodipine, indapamide
Study NCT05899920 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood samples will be taken for pharmacokinetics and pharmacogenetics
Description: To assess antihypertensive drugs concentration (lisinopril, valsartan, amlodipine, indapamide
Study NCT04939116 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Orally administered placebo capsule
Study NCT06556342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FRD001
Description: FRD001 injection is a lipid-based second-generation ultrasound contrast agent. FRD001 injection in ultrasound contrast imaging could enhance the differentiation between benign and malignant ovarian masses in women, using gray-scale and power Doppler ultrasound as controls.
Study NCT05806411 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Analysis of calcific aortic valves
Description: Microbiologic analysis of calcofic aortic valves
Study NCT05248867 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo solution for injection
Study NCT05248867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-151586
Description: AGN-151586 solution for injection
Study NCT05248867 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AGN-151586
Description: AGN-151586 solution for injection
Study NCT05005793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate
Description: Oral sodium bicarbonate at 0.5 mEq/kg-lean body weight/day
Study NCT05005793 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo at 0.5 mEq/kg-lean body weight/day
Study NCT06556732 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Eplereone
Description: Group A (study group): 50 patients received eplerenon 25 mg daily plus amiodarone and other medications not including non-dihydropyridine calcium channel blocker or digoxin.
Study NCT06556732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplereone
Description: Group A (study group): 50 patients received eplerenon 25 mg daily plus amiodarone and other medications not including non-dihydropyridine calcium channel blocker or digoxin.
Study NCT06409923 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stimulation of mandibular growth.
Description: orthodontic treatment where a retrognathic mandibula is put into an anterior position to stimulate mandibular growth. This will happen by either the MA-invisalign system or the herbst appliance
Study NCT05593146 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: modified anteversion angle placement(( α-15°)±10°)
Description: Preoperative examination was conducted to determine a safe surgical margin in all patients. A 3D printed osteotomy guide combined with a 3D printed prosthesis pre- designed anteversion angle is assembled for reconstruction after tumor resection.~Once completed, intraoperative X-ray fluoroscopy was applied to evaluate the anteversion angle of the acetabular component. If the anteversion angle doesn't meet the predetermined criteria, it needs to be adjusted until it does.
Study NCT05593146 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: conventional anteversion angle placement ( α±10°)
Description: Preoperative examination was conducted to determine a safe surgical margin in all patients. A 3D printed osteotomy guide combined with a 3D printed prosthesis with predesigned anteversion angle is assembled for reconstruction following tumor resection.~Once completed, intraoperative X-ray fluoroscopy was applied to evaluate the anteversion angle of the acetabular component. If the anteversion angle doesn't meet the predetermined criteria, it needs to be adjusted until it does.
Study NCT05097781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 blocking antibody
Description: All patients with more than one distant metastatic lesions will accept at least one site of radiotherapy and PD-1 blockade at the same time.
Study NCT04899102 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time-Restricted, Intermittent Fasting
Description: A special type of diet for 6 weeks, called time-restricted, intermittent fasting.
Study NCT05610683 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemodialysis sessions using SHFVE dialyzer (VieX™) or the MCO (Theranova 500™) dialyzer
Description: Patients will receive thrice weekly 4 hours hemodialysis sessions during 3 months
Study NCT05984095 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: The intervention was administered in a telerehabilitation fashion through a videocall on the phone or tablet, by a physiotherapist, in a one-to-one session.
Study NCT05984095 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telerehabilitation
Description: The intervention was administered in a telerehabilitation fashion through a videocall on the phone or tablet, by a physiotherapist, in a one-to-one session.
Study NCT06304428 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Deprescribing Care Model
Description: The Deprescribing Care Model is designed to deprescribe fall related medications (FRIDs)
Study NCT06304428 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bone Health Service Model
Description: The Bone Health Service Model is designed to provide osteoporosis evaluation and management
Study NCT06304428 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Injury Prevention Service Model
Description: The Injury Prevention Service Model provides both the Deprescribing Care Model and the Bone Health Service Model.
Study NCT06290830 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Abdominal massage group
Description: abdominal massage creates reflex and mechanical movement of the intestines by applying pressure to the rectum and changing intra-abdominal pressure.
Study NCT06290830 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kegel Exercises group
Description: Kegel exercises (also called pelvic floor exercises) have a functional connection with other core muscles and contribute to the synergistic effect of the abdominal and pelvic floor muscles
Study NCT06290830 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Both abdominal massage and kegel exercises to gether
Description: with both exercises are performed to accelerate the peristalsis movement by mechanical movements
Study NCT05392127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR0302 Tablets
Description: SHR0302 Tablets once daily
Study NCT05392127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam Maleate Tablets
Description: Midazolam Maleate Tablets single dose
Study NCT05392127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin Sodium Tablets
Description: Warfarin Sodium Tablets single dose
Study NCT05392127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole Enteric Capsules
Description: Omeprazole Enteric Capsules single dose
Study NCT05392127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin K1 Tablets
Description: Vitamin K1 Tablets once daily
Study NCT05392127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repaglinide Tablets
Description: Repaglinide Tablets single dose
Study NCT04459468 — intervention group
Intervention type: DRUG
Intervention: Lipiodol
Description: Lipiodol TACE procedure
Study NCT05147142 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low Intensity Focused Ultrasound
Description: Brainsonix BX Pulsar 1002
Study NCT05147142 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Intensity Focused Ultrasound
Description: Brainsonix BX Pulsar 1002
Study NCT06660667 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SAR402663
Description: Pharmaceutical form:Liquid formulation-Route of administration:Intravitreal injection
Study NCT06660667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diluent
Description: Pharmaceutical form:Liquid solution-Route of administration:Intravitreal injection
Study NCT06663072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Safety-Run In: Starting Dose: 500 mg IM on Days 1, 15, and 29 of Cycle 1; followed by 500 mg IM on Days 1 and 29 of every cycle thereafter for a total of 9 doses.~Dose Expansion: 500 mg IM: Days 1, 15, and 29 of Cycle 1; followed by 500 mg IM on Days 1 and 29 of every cycle thereafter for a total of 9 doses.
Study NCT06663072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-DOTATATE
Description: Safety-Run In: Starting Dose: 7.4 GBq (200 mCi) IV every 8 weeks for a total of 4 Cycles~Dose Expansion:177Lu-DOTATATE7.4 GBq (200 mCi) IV or 3.7 GBq (100 mCi) IV: IV dose every 8 weeks for a total of 4 Cycles.
Study NCT05106036 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Support Decision Tool
Description: Participants whose home blood pressure reading average is systolic ≥ 130 and diastolic ≥ 80 will trigger the Clinical Decision Support (CDS) tool to assist their physicians with their blood pressure management. Home BP data will be averaged each month via Omron Connect app on the patients' smartphone, which is programmed to send home BP readings to MyChart via Apple or Google Health. We have designed CDS to present treatment choices of antihypertensive medication regimen based on medications patients are currently taking. For example, patients who are currently taking an angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB), our CDS algorithm will recommend addition of a calcium channel blocker as the first tier of recommendation and thiazide diuretics as second tier of recommendation. Laboratory data and home BP in the past month will be presented in a clear and simple manner for the clinicians to activate and use to optimize BP control.
Study NCT05757193 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DeltaG (250 mg/kg)
Description: 250 mg/kg of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate
Study NCT05757193 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DeltaG (500 mg/kg)
Description: 500 mg/kg of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate
Study NCT04954040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine Pill + Azithromycin Pill
Description: Hydroxychloroquine. 1st day 200mg 2-0-2; 2nd to 5th day 200mg 1-0-1 Azithromycin.~1st day 500m 0-1-0, 2nd to 5th day 250mg 0-1-0
Study NCT04954040 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SOC
Description: Acetaminophen or Metamizole. Antitussives if needed.
Study NCT05744206 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrocardiogram measurements by holter device and patch-type electrocardiographic at the same time
Description: The patient is measured electrocardiogram simultaneously through a holter device and patch-type electrocardiograph
Study NCT05226819 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: PPI quadruple therapy
Description: Among these outpatients, H. pylori-negative patients don't give any intervention. But H. pylori-positive patients are given rabeprazole 10mg + amoxicillin 1000mg + clarithromycin 500mg + colloidal bismuth tartrate 220mg bid for 14 days. After 4-6 weeks of completing eradication therapy, 13C-UBT is performed.
Study NCT06658301 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: plyometric push up exercises
Description: The subjects will starts with push-up position with hands on the floor, place slightly wider than shoulder width apart and their feet together. Keeping their back flat, slowly lower the body toward the ground. Then in one explosive movement, push-up and away from the floor as quickly as possible, bring their hands off the floor.
Study NCT06658301 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: swiss ball push up exercises
Description: . The subjects will start with kneeling position so that they will face the ball. Place their hands on top of the ball so that they can bend their elbows towards the body. Straight the legs out and raise themselves slightly higher so that they can be on their toes. Stay in neutral position. Straighten their arms at the elbows, so that they can push themselves up from the ball.
Study NCT06669416 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Taste Alteration Self-Assessment
Description: The nurse-led intervention involves using a valid/reliable TA assessment tool (Chemotherapy-induced Taste Alterations Scale (CiTAS) and teaching the patient to select assessment-driven interventions to manage TA symptoms.
Study NCT06669416 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Taste Alternation Self-Management
Description: The nurse-led intervention involves teaching the patient to use the assessments and the evidence-based Patient Education Sheet to select assessment-driven interventions to manage their symptoms. Data will be collected about the specific actions prescribed in the teaching tool and to identify which interventions were used and their overall impact.
Study NCT05599100 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STAR-Caregivers Virtual Training & Follow-up (STAR-VTF)
Description: For 6-8 weeks, caregivers will complete online training modules asynchronously. Caregivers will be instructed to complete one module per week. The content of the modules is as follows: Module 1 introduces caregivers to the behavioral treatment of dementia, realistic expectations, and effective communication; Module 2 covers the ABC (antecedents, behaviors, consequences) approach to problem-solving, including rationale and development of an ABC plan; Module 3 instructs caregivers to review the ABC plan and revise as needed; Module 4 covers pleasant events and managing negative thinking; Module 5 instructs caregivers to review the ABC plan, pleasant activities schedule, and to revise as needed; Module 6 covers coping with caregiving and maintaining gains. Each module takes about 45 minutes to complete. The modules use text, pictures, and illustrations with a voiceover presentation. Caregivers will receive the online training modules in their preferred language (English or Spanish).
Study NCT05870865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASN008
Description: ASN008 topical gel applied twice daily.
Study NCT05870865 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: ASN008 Matching Vehicle
Description: The ASN008 matching vehicle formulation matches the formulation of each ASN008 topical gel dose, but contains no ASN008.
Study NCT06022926 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: warmed with electric blankets
Description: warmed with electric blankets
Study NCT06022926 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: patients without warming
Description: patients without warming: no electric blanket will be used, and no heating will be applied to this group of patients.
Study NCT04585958 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT04585958 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT04585958 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT04585958 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo echocardiography
Study NCT04585958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO
Study NCT04585958 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab Deruxtecan
Description: Given IV
Study NCT06017973 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: MRI scan including arterial spin labelling of the brain
Description: Arterial Spin Labelling sequence, T2-weighted FLAIR images and T1-weighted images and diffusion weighted imaging sequence will be recorded
Study NCT06017973 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: CT perfusion scan of the brain
Description: Siemens Naeotom Alpha with quantum technology (photon-counting)
Study NCT06017973 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: FDG-PET scan of the brain
Description: An FDG-PET scan will be acquired on a GE Signa 3T PET-MR scanner. FDG-PET images will be assessed for focal hypermetabolism, including semiquantitative analysis of the maximal standard uptake value (SUVmax) relative to the SUVmax of the pons (SUVr pons)
Study NCT05107674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NX-1607
Description: Oral NX-1607
Study NCT05107674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel IV
Study NCT06251115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QY-1-T
Description: QY-1-T is a TCR-T drug targeting HBV-related HCC
Study NCT05394857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1314
Description: SHR-1314 subcutaneously
Study NCT06253871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IAM1363
Description: Oral, immediate release capsules of IAM1363
Study NCT06625528 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: open flap debridement
Description: does lyophilized platelet rich fibrin combined with open flap debridement or combination of open flap debridement, lyophilized platelet rich fibrin and nano-crystalline hydroxyapatite bone substitute can add benefits to open flap debridement alone or not
Study NCT06625528 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: open flap debridement
Description: does lyophilized platelet rich fibrin combined with open flap debridement or combination of open flap debridement, lyophilized platelet rich fibrin and nano-crystalline hydroxyapatite bone substitute can add benefits to open flap debridement alone or not
Study NCT05923008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI130
Description: Subjects will receive IBI130 until unacceptable toxicity, disease progression, withdrawal of consent, occurrence of other reasons for discontinuing study therapy, or for a maximum of 24 months of treatment, whichever occurs first.
Study NCT05485129 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BIORICS
Description: Wearing BIORICS in their ear and perform mental arrhythmic test, relaxation exercises and Stroop test
Study NCT05192707 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: TcPO2 measurement on the upper limb
Description: Measurement of the transcutaneous Oxygen Pressure in the upper limb of 30 healthy volunteers and of at least 30 patients.